United Laboratories International (ULIHF) Stock Price, News & Analysis

Company Overview

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin products, nervous system drugs, vitamins, veterinary drugs, and vacant gelatin capsules. It also provides intermediate products, such as 6-aminopenicillanic acid, tert-octylammonium clavulanate, anhydrous sodium carbonate sterile, and penicillin G potassium first crystal. In addition, the company manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products, as well as offers management services. It has operations in the People's Republic of China, India, Europe, the Middle East, South America, rest of Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.

Key Stats

• Today's Range: $1.14 to $1.14
• 50-Day Range: $1.14 to $1.24
• 52-Week Range: $1.14 to $1.70
• Volume: N/A
• Average Volume: 1,860 shs
• Market Capitalization: N/A
• P/E Ratio: 2.59
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

United Laboratories International Stock Analysis - MarketRank™

United Laboratories International scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for United Laboratories International.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of United Laboratories International is 2.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.06.

Price to Earnings Ratio vs. Sector

The P/E ratio of United Laboratories International is 2.59, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.21.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

United Laboratories International has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in United Laboratories International has recently increased by 0.18%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

United Laboratories International does not currently pay a dividend.

Dividend Growth

United Laboratories International does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for United Laboratories International this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, United Laboratories International insiders have not sold or bought any company stock.

Percentage Held by Institutions

2.61% of the stock of United Laboratories International is held by institutions.

Company Calendar

• Today: 8/28/2026
• Next Earnings (Estimated): 8/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ULIHF
• CIK: N/A
• Web: www.tul.com.cn
• Phone: 852-2687-1033
• Fax: N/A
• Employees: 15,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 2.59
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A